Clinical Trials
16 trialsNCT07012044 2026-05-27
A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia
National Cancer Institute (NCI)
Phase 1 Recruiting
NCT04187703 2026-05-18
5-Azacitidine and Decitabine Epigenetic Therapy for Myeloid Malignancies
Case Comprehensive Cancer Center
Phase EARLY_PHASE1 Recruiting
NCT06928662 2026-05-15
Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse
Fred Hutchinson Cancer Center
Phase 1/2 Recruiting
NCT06930651 2026-05-06
A Phase I/II Study of CAR.70-Engineered IL15-Transduced Cord Blood-Derived NK Cells With TGF-beta Receptor 2 (TGFBR2) Knock Out in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapsed/Refractory Myeloid Malignancies
M.D. Anderson Cancer Center
Phase 1/2 Recruiting
NCT07374029 2026-05-05
Adoptive T Cell Therapy With DC/AML Fusion Vaccine Plus Decitabine and Venetoclax in AML
Beth Israel Deaconess Medical Center
Phase 1 Recruiting
NCT05586074 2026-04-28
HEC73543 Versus Salvage Chemotherapy in R/R FLT3-ITD AML
Sunshine Lake Pharma Co., Ltd.
Phase 3 Recruiting
NCT06129734 2026-04-27
Decitabine and Venetoclax Treatment as Maintenance Therapy in Patients Post Allograft Stem Cell Transplant
Case Comprehensive Cancer Center
Phase 1/2 Recruiting
NCT03418038 2026-04-16
Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia
Mayo Clinic
Phase 2 Recruiting
NCT07177079 2026-04-09
High-dose Ascorbate (HDA) in Combination With Standard of Care Azacitidine and Venetoclax in Acute Myeloid Leukemia (AML)
University of Iowa
Phase 1 Recruiting
NCT06327685 2026-04-01
Avapritinib With Decitabine in Patients With SM-AHN
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Recruiting
NCT00801489 2026-03-30
Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT05796570 2026-03-19
MORE
Dana-Farber Cancer Institute
Phase 2 Recruiting
NCT06379360 2026-03-19
Maintenance Therapy of Hypomethylating Agent (HMA) in Favorable Risk Acute Myeloid Leukemia (AML) Patients
The First Affiliated Hospital of Soochow University
Phase 2 Recruiting
NCT05636514 2026-03-18
CELESTIAL-MDS
Clinical Hub for Interventional Research (CHOIR)
Phase 1 Recruiting
NCT04282187 2026-03-16
Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms
University of Washington
Phase 2 Recruiting
NCT06561074 2026-03-16
A Phase 2 Study to Evaluate Efficacy of Calaspargase Pegol-mknl and Decitabine Combined With Venetoclax in Pediatric, Adolescent, and Young Adult Patients With Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia (T-ALL) and T- Cell Lymphoblastic Lymphoma (T-LLy)
M.D. Anderson Cancer Center
Phase 2 Recruiting